Coronavirus Tests India’s Vaccine Makers in R&D Capability (Nikkei Asian Review)

At least six Indian pharmaceutical companies have joined the global race to develop a novel coronavirus vaccine, giving a sector better known for making generic copies of drugs a platform to show its innovative capability.

The World Health Organization has listed three Indian companies — Zydus Cadila, Serum Institute of India and Bharat Biotech — that are working on a vaccine. In addition, Hyderabad-based companies Biological E and Indian Immunologicals as well as Bangalore-based Mynvax are also involved in development. READ MORE (CACHED ARTICLE)

Similar Posts:

• India Moves Up the Ranks of Asia300 Companies (Nikkei Asian Review)
• Seven Reasons India Is Primed for Growth (Enterprising Investor)
• CLSA Equity Strategist Says India is the Best BRICs Investment Destination (LM)
• Into Africa: India Vies With China for Post-pandemic Clout (Nikkei Asian Review)
• India to Offer More Investment Options Through ADRs (The Asset)
• General Motors to Stops Selling Chevrolet in India (BusinessLine)
• How India (Mostly) Benefits From Low Oil Prices (The Economic Times)
• India’s Largest Cement Maker “Circumventing The Dollar” In Russian-Coal-For-Yuan Deal (Zero Hedge)
• Aberdeen CIO: India Will Surpass China for Growth (FE Trustnet)
• Emerging Markets Like India: The Next Frontier for Surgical Innovation (Cambridge Consultants)
• Is India’s lost generation a systemic risk? (CNBC)
• Hermes’ Greenberg: Overweight in India But Avoiding Modi Stocks (FE Trustnet)
• OMGI’s Crabb: India Consumer Stocks on “Very Stretched Multiples” (FE Trustnet)
• ‘Once-in-a-lifetime Opportunity’: How a Mass Lockdown at the World’s Biggest iPhone Factory is India’s Big Chance to Beat out China as Apple’s Favorite Supplier (Fortune)
• Warren Buffett: India Has ‘Incredible’ Potential. Why Hasn’t He Invested? (CNN Money)